Organon is selling its JADA post-partum haemorrhage (PPH) treatment system to Laborie Medical in a deal valued at up to $465m. The US-based company will receive $440m at the deal’s closing, with ...

Laborie Medical Technologies Corp. has agreed to acquire Jersey City-based Organon‘s JADA System for up to $465 million. The deal includes $440 million to be paid at closing and a potential payment of ...

Organon & Co. OGN announced the completion of the divestiture of its JADA System to Laborie Medical Technologies Corp. The deal is worth up to $465 million, including $440 million paid at closing and ...

The JADA® System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join Laborie, strengthening the company's commitment to improving maternal health. Joining an ...

The MarketWatch News Department was not involved in the creation of this content. The acquisition expands Laborie's obstetrics portfolio and demonstrates the company's commitment to delivering ...

Please provide your email address to receive an email when new articles are posted on . The JADA system decreased abnormal postpartum uterine bleeding in vaginal and cesarean birth, regardless of ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women’s health company, today announced clearance by the U.S. Food and Drug Administration (FDA) of the Special 510(k) for ...

The MarketWatch News Department was not involved in the creation of this content. The JADA(R) System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join ...